Latest Commercial Partnerships News

Bio-Gene Technology has raised A$3.21 million to complete critical safety studies for its novel insecticide Flavocide and ramp up production of its natural insecticide Qcide, advancing its path to commercialisation in multiple global markets.

Vectus Biosystems has secured $791,000 through a placement to accelerate its lead fibrosis drug VB0004's Phase IB clinical trial and advance other drug candidates.

Critica Limited has achieved a major leap in rare earth product quality at its Jupiter Project, producing a Mixed Rare Earth Oxide with approximately 97% Total Rare Earth Oxide and strong recovery rates that bolster its mine-to-magnet ambitions.

Avecho Biotechnology has bolstered its cash reserves by $1.9 million through the exercise of listed options, positioning the company for a pivotal Phase III interim analysis readout for its insomnia treatment.

FlexiRoam has secured a commercial partnership to embed its AI-powered mobile data platform into all Tune Protect travel insurance Preset Policies, creating a scalable engagement channel for ancillary revenue.

Vectus Biosystems appoints Dr Tara Speranza as CEO and CTO to accelerate development of lead fibrosis drug VB0004 with performance-linked incentives.

Cynata Therapeutics has secured A$1.5 million through an institutional placement priced at a 22.5% discount, aiming to extend its cash runway ahead of pivotal Phase 3 and Phase 2 trial results expected in May and June 2026.

dorsaVi has launched a multi-year partnership with Taiwan’s ITRI and NTU to develop its proprietary RRAM platform at the 22-nm node, complemented by a new advisory board and neuromorphic IP acquisition, positioning the company at the forefront of ultra-edge AI hardware.

Avecho Biotechnology has exceeded its Phase III CBD insomnia trial recruitment target by 16%, setting the stage for a more robust interim analysis scheduled for June 2026. The company’s commercial partnership with Sandoz AG and strengthened patent portfolio underpin its Australian market strategy.

Sea Forest Limited’s 3Q26 revenue surged 92% to $1.1 million, boosted by expanding SeaFeed™ sales and a pioneering low-carbon wool launch with Theory. New cattle supply deals raise herd commitments to 131,000, underpinning growth amid supportive government policies.

Way2VAT reported a 95% surge in Q1 FY26 revenue to $2.05 million, driven by its RBC acquisition and expanding client base, while preparing to launch an e-invoicing platform integrating AI-powered APAI technology.

Vitrafy Life Sciences completed Phase II of its U.S. Military platelet cryopreservation study with strong results for a simplified no-wash process, accelerating commercial interest and progressing FDA device registration despite manufacturing delays.